FORT DETRICK, Md. –
On August 12, 2022, the Defense Department’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) awarded a follow-on Other Transaction Authority (OTA) for Production agreement to kaléo, Inc. The contract follows a previous OTA awarded to kaléo in 2019 to develop the 10mg NAI in collaboration with the JPM CBRN Medical and the Chemical and Biological Defense Program (CBDP). Under this follow-on OTA, awarded through the Army Contracting Command, kaléo will manufacture and deliver 10mg naloxone autoinjectors (NAI) as a residual capability to the DoD’s Special User Groups, as well as an emergency stockpile no later than September 2022.
The ROCS program followed a Middle Tier Acquisition pathway to rapidly develop and provide a fieldable product in under three years, specifically for military personnel and chemical incident emergency responders. The 10mg NAI is designed as a rescue treatment for use by non-medically trained users to protect against exposure to ultra-potent opioids, including fentanyl analogue exposure, or for use before suspected opioid exposure. Fielding the 10mg NAI gives the Services access to a life-saving medical countermeasure that allows the warfighter to remain ambulatory and evacuate to a higher role of care. Additionally, this product supports congressional interest in helping our interagency partners remain tactically ready in the national war against opioids and allied nation inquiries for access.
Contract number: MCDC-19-03-04-004.
About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability. To learn more about the JPM CBRN Medical, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow JPEO-CBRND on social media at @JPEOCBRND.
About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological, and nuclear (CBRN) threats. The JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. The JPEO-CBRND facilitates the rapid response, advanced development, manufacturing, and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats such as COVID-19. To learn more about the JPEO-CBRND’s COVID-19 response, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow the JPEO-CBRND on social media at @JPEOCBRND.